Dipyridamole and adenosinergic pathway in Covid-19: a juice or holy grail

Abstract Background Coronavirus disease 2019 (Covid-19) is an infectious worldwide pandemic triggered by severe acute respiratory coronavirus 2 (SARS-CoV-2). This can lead to pro-inflammatory activation with associated lung injury and distress syndrome. Main body of the abstract SARS-CoV-2 infection linked inhibition adenosine phosphodiesterase. Dipyridamole (DIP) a nucleoside transport phosphodiesterase inhibitor so that it may potentially affect its accompanying inflammations. Therefore, primary objective this mini-review study was elucidate potential beneficial impacts DIP on adenosinergic pathway in Covid-19. A systemic search done using online databases relevant keywords. The findings present illustrated directly or indirectly, through augmentation phosphodiesterase, mitigates Covid-19 outcomes. Conclusion Our concluded has therapeutic effect management treatment could be attained either directly, anti-SARS-CoV-2, anti-inflammatory, anti-platelets properties, extracellular adenosine, which anti-inflammatory immune-regulatory effects. However, extensive randomized clinical trials, prospective research area are required demonstrate safety efficacy modulators